Evidence map›Paper›PMID 41614659›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

FAPα

Huiyao Gu, Zhenfeng Dai, Xi Huang, Enfan Zhang, Xinyuan Dai, Haoguang Chen, Wen Cao, Jinna Zhang, Yifan Hou, Haimeng Yan and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Huiyao GuBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhenfeng DaiBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xi HuangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Enfan ZhangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xinyuan DaiBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Haoguang ChenBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Wen CaoBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jinna ZhangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yifan HouBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Haimeng YanBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yang YangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Li YangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yi LiBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Wenlong LinInstitute of Immunology and the Second Affiliated Hospital, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0002-8763-7893
Zhen CaiBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jingsong HeBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Funding

Medical and Health Science and Technology Project of Zhejiang Province 2023KY673National Natural Science Foundation of China 82173267National Natural Science Foundation of China 82200216National Natural Science Foundation of China 82270206National Natural Science Foundation of China 82300232
6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long-term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse. Accumulating evidence highlights the tumor immune microenvironment, especially macrophages, as a key contributor to immunotherapy failure in MM. Herein, we identified a subset of MM-associated macrophages with high expression of fibroblast activation protein alpha (FAPα), defined as FAPα

Indexed as

B7-H1 AntigenCellular SenescenceEndopeptidasesGelatinasesMacrophagesMembrane ProteinsMultiple MyelomaSerine EndopeptidasesT-LymphocytesAnimalsFemaleFibroblast Activation Protein AlphaHumansMiceTumor MicroenvironmentB7-H1 AntigenCD274 protein, humanEndopeptidasesFibroblast Activation Protein AlphaGelatinasesMembrane ProteinsSerine EndopeptidasesFAPαimmune escapeimmunotherapymacrophagemultiple myelomaPD‐L1vimentin

Identifiers

PMID41614659
PMCPMC13042965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.